Drug Profile
Research programme: haemophilia therapeutics - Takeda/Avadel Pharmaceuticals
Latest Information Update: 15 Jan 2019
Price :
$50
*
At a glance
- Originator Baxter International; Flamel Technologies
- Developer Avadel Pharmaceuticals; Shire
- Class Blood coagulation factors
- Mechanism of Action Blood coagulation factor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Haemophilia
Most Recent Events
- 08 Jan 2019 Shire has been acquired and merged into Takeda
- 04 Nov 2017 No recent reports of development identified for research development in Haemophilia in France (IV, Infusion)
- 04 Nov 2017 No recent reports of development identified for research development in Haemophilia in USA (IV, Infusion)